<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529070</url>
  </required_header>
  <id_info>
    <org_study_id>FWH20200116H</org_study_id>
    <nct_id>NCT04529070</nct_id>
  </id_info>
  <brief_title>Nightmare Rescripting and Rehearsal</brief_title>
  <official_title>Nightmare Rescripting and Rehearsal: Testing a 10-Minute Intervention to Treat Recurring Distressing Dreams in Primary Care.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>kathleen mcnamara</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mike O'Callaghan Military Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy&#xD;
      administered by non-mental health professionals in a Primary Care setting. This treatment, to&#xD;
      be called 'Nightmare Rescripting and Rehearsal Therapy' (NRRT) would arm Primary Care medical&#xD;
      personnel with a nonpharmacologic, ten minute intervention for treating recurring nightmares.&#xD;
&#xD;
      The study will provide sleep hygiene education to both the control and experiment groups,&#xD;
      NRRT to the experiment group only, and compare their Nightmare Distress Questionnaire and&#xD;
      Nightmare Frequency Tool at two (2), four (4), and six (6) week intervals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective Randomized Controlled Trial to determine if a standard of care sleep&#xD;
      hygiene handout plus a brief 10 minute intervention for recurring nightmares (Nightmare&#xD;
      Rescripting and Rehearsal Therapy) reduces scores on the Nightmare Distress Questionnaire and&#xD;
      Nightmare Frequency Tool, when compared to patients solely receiving a handout outlining&#xD;
      sleep hygiene techniques. Individuals with a minimum score on the Nightmare Distress&#xD;
      Questionnaire and Nightmare Frequency Tool of 15 out of a possible 52 who meet all other&#xD;
      inclusion criteria will be invited to participate.&#xD;
&#xD;
      A clinically significant reduction will be considered if a decrease in Nightmare Distress and&#xD;
      Frequency measures is greater than or equal to 25% from baseline. Secondary outcomes will&#xD;
      include PCL-5 (PTSD), PHQ9 (Depression), GAD7 (Anxiety), ISI (Insomnia Severity Index)&#xD;
      scores.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nightmare distress Questionnaire (change from nightmare distress baseline from screening at each 4 visits)</measure>
    <time_frame>screening, visit 1 (week 0), visit 2 (week 2 +/- 1 week), visit 3 (week 4 +/- 1 week), visit 4 (week 6 +/- 1 week)</time_frame>
    <description>13 questions, 0-4. 0 indicates lower level of distress and effects as related to nightmares.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nightmare Frequency in the past week (change from nightmare frequency screening baseline at each 4 visits)</measure>
    <time_frame>screening, visit 1 (week 0), visit 2 (week 2 +/- 1 week), visit 3 (week 4 +/- 1 week), visit 4 (week 6 +/- 1 week)</time_frame>
    <description>Boxes numbered one to 31. Pt circles the number corresponding to the number of days they had a nightmare in the past month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Posttraumatic Stress Disorder Checklist (PTSD)</measure>
    <time_frame>screening, visit 1 (week 0), visit 2 (week 2 +/- 1 week), visit 3 (week 4 +/- 1 week), visit 4 (week 6 +/- 1 week)</time_frame>
    <description>The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. The questionnaire is self-report and may be completed in 5-10 minutes. Lower score indicates less severity of PTSD symptoms but is broad enough to pick up a wide base of patients with possible PTSD. Higher scores indicate greater severity and also offeres greater sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II</measure>
    <time_frame>screening, visit 1 (week 0), visit 2 (week 2 +/- 1 week), visit 3 (week 4 +/- 1 week), visit 4 (week 6 +/- 1 week)</time_frame>
    <description>BDI-II. This questionnaire self-report and is made up of 21 groups of statements designed to measure attitudes and symptoms of depression severity. Each question has options that are scored on a scale of 0 to 3. Higher scores equals more severity of depression symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Anxiety Disorder (anxiety)</measure>
    <time_frame>screening, visit 1 (week 0), visit 2 (week 2 +/- 1 week), visit 3 (week 4 +/- 1 week), visit 4 (week 6 +/- 1 week)</time_frame>
    <description>GAD-7. Objective screening tool to use to identify severity of: (Generalized Anxiety Disorder, Panic Disorder, Social Phobia and PostTraumatic Stress Disorder). 7 questions with options 0-3 and with a higher score indicating greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index (insomnia)</measure>
    <time_frame>screening, visit 1 (week 0), visit 2 (week 2 +/- 1 week), visit 3 (week 4 +/- 1 week), visit 4 (week 6 +/- 1 week)</time_frame>
    <description>ISI. Measures insomnia problems occurring in the last 2 weeks. 7 questions with added up scores. Higher score indicates greater symptom severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Nightmare</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Intervention + Standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nightmare Rescripting and Rehearsal: a 10 minute intervention for Primary Care plus Sleep Hygiene handout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care Sleep Hygiene handout alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nightmare Rescripting and Rehearsal</intervention_name>
    <description>This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy ('Nightmare Rescripting and Rehearsal Therapy' (NRRT)) administered by non-mental health professionals in a Primary Care setting.</description>
    <arm_group_label>Intervention + Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>standard of care</description>
    <arm_group_label>Intervention + Standard of care</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        **Patients must be able to get care at Nellis Air Force Base (a military installation) in&#xD;
        order to participate in this study**&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Active Duty members and DoD beneficiaries.&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Recurring disturbing dreams (at least three times per month for the past one month)&#xD;
&#xD;
          -  Participants must score a 15 out of a possible 52 on the Nightmare Distress&#xD;
             Questionnaire and Nightmare Frequency Tool in order to qualify.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Aged less than 18 years old&#xD;
&#xD;
          -  Unwilling to refrain from taking an over the counter or prescription medication for&#xD;
             the purpose of improving sleep during the course of the study.&#xD;
&#xD;
          -  Participants that score less than a 15 out of a possible 52 on the Nightmare Distress&#xD;
             Questionnaire and Nightmare Frequency will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jill M Clark, MBA</last_name>
    <phone>7026533298</phone>
    <email>jill.m.clark15.ctr@mail.mil</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mike O'Callaghan Military Medical Center</name>
      <address>
        <city>Nellis Air Force Base</city>
        <state>Nevada</state>
        <zip>89191</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda J Crawford, MSHS</last_name>
      <phone>702-653-3298</phone>
      <email>amanda.j.crawford.ctr@mail.mil</email>
    </contact>
    <contact_backup>
      <last_name>Jill M Clark, MBA/HCM</last_name>
      <phone>702-653-3298</phone>
      <email>jill.m.clark15.ctr@mail.mil</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association.</citation>
  </reference>
  <reference>
    <citation>Belicki K. (1992). The relationship of nightmare frequency to nightmare suffering with implications for treatment and research. Dreaming 2 143-148. 10.1037/h0094355</citation>
  </reference>
  <reference>
    <citation>Böckermann, M., Gieselmann, A., &amp; Pietrowsky, R. (2014). What does nightmare distress mean? Factorial structure and psychometric properties of the Nightmare Distress Questionnaire (NDQ). Dreaming, 24(4), 279-289. https://doi.org/10.1037/a0037749</citation>
  </reference>
  <reference>
    <citation>Collen JF, Williams SG, Lettieri CJ. Doomed to Repeat History: The Burden of Trauma-Related Nightmares in Military Personnel. J Clin Sleep Med. 2018 Mar 15;14(3):303-305. doi: 10.5664/jcsm.6964.</citation>
    <PMID>29458710</PMID>
  </reference>
  <reference>
    <citation>Creamer JL, Brock MS, Matsangas P, Motamedi V, Mysliwiec V. Nightmares in United States Military Personnel With Sleep Disturbances. J Clin Sleep Med. 2018 Mar 15;14(3):419-426. doi: 10.5664/jcsm.6990.</citation>
    <PMID>29510796</PMID>
  </reference>
  <reference>
    <citation>Harb, G. C., Forbes, D., Phelps, A., Gehrman, P. R., Cook, J. M., Gamble, G. &amp; Ross, R. J. (2010). Treatment Manual for Imagery Rehearsal + cCBT for Insomnia.</citation>
  </reference>
  <reference>
    <citation>Köthe, M. &amp; Pietrowsky, R. (2001). Behavioral effects of nightmares and their correlations to personality patterns. Dreaming, 11, 43-52.</citation>
  </reference>
  <reference>
    <citation>Krakow B, Kellner R, Neidhardt J, Pathak D, Lambert L. Imagery rehearsal treatment of chronic nightmares: with a thirty month follow-up. J Behav Ther Exp Psychiatry. 1993 Dec;24(4):325-30.</citation>
    <PMID>8077451</PMID>
  </reference>
  <reference>
    <citation>Krakow B, Hollifield M, Schrader R, Koss M, Tandberg D, Lauriello J, McBride L, Warner TD, Cheng D, Edmond T, Kellner R. A controlled study of imagery rehearsal for chronic nightmares in sexual assault survivors with PTSD: a preliminary report. J Trauma Stress. 2000 Oct;13(4):589-609.</citation>
    <PMID>11109233</PMID>
  </reference>
  <reference>
    <citation>Levin R, Nielsen TA. Disturbed dreaming, posttraumatic stress disorder, and affect distress: a review and neurocognitive model. Psychol Bull. 2007 May;133(3):482-528. Review.</citation>
    <PMID>17469988</PMID>
  </reference>
  <reference>
    <citation>Pruiksma, K. E., Slavish, D., Wardle, S. Ojeda, A., Taylor, D., Peterson, A., Kelly, K., Maur, D., Mintz, J., Litz, B., Borah, E., Brundige, A., Young-McCaughan, S., Williamson, D. (2019). Prevalence and correlates of nightmares in Active Duty Service Members. Sleep, (42)1, A267. https://doi.org/10.1093/sleep/zsz067.667</citation>
  </reference>
  <reference>
    <citation>Seda G, Sanchez-Ortuno MM, Welsh CH, Halbower AC, Edinger JD. Comparative meta-analysis of prazosin and imagery rehearsal therapy for nightmare frequency, sleep quality, and posttraumatic stress. J Clin Sleep Med. 2015 Jan 15;11(1):11-22. doi: 10.5664/jcsm.4354.</citation>
    <PMID>25325592</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mike O'Callaghan Military Hospital</investigator_affiliation>
    <investigator_full_name>kathleen mcnamara</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>nightmare rescripting</keyword>
  <keyword>dreams</keyword>
  <keyword>behavioral health</keyword>
  <keyword>sleep</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan on sharing data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

